Results 141 to 150 of about 16,492 (195)

Clinician-level variation in lipid management for secondary prevention of atherosclerotic cardiovascular disease: Opportunities for practice improvement. [PDF]

Am J Prev Cardiol
Nguyen DQ, Hwang J, Rohatgi A, Joshi PH, Khera A, Peterson ED, Navar AM.   +6 more
europepmc   +1 more source

Expanding the genotypic spectrum of PCSK1 deficiency: A novel mutation in severe neonatal diarrhea. [PDF]

JPGN Rep
Saraceno E, Faini AC, Deaglio S, Pellegrini M, Buganza R, Giuliani F, Calvo PL, Pinon M.   +7 more
europepmc   +1 more source

Impact of mRNA and protein isoforms in lipoprotein metabolism and how to modulate them. [PDF]

Curr Opin Lipidol
Martinovich KM, Cale JM, Aung-Htut MT.
europepmc   +1 more source

Advances in Beyond Statin Lipid Therapies for ASCVD Risk Reduction. [PDF]

J Atheroscler Thromb
Shimabukuro M.
europepmc   +1 more source

A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]

Front Pharmacol
Liu HH, Li S, Li JJ.
europepmc   +1 more source

Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study. [PDF]

Front Endocrinol (Lausanne)
Wu JY, Lin YM, Hsu WH, Liu T, Tsai YW, Huang PY, Chuang MH, Yu T, Lai CC.   +8 more
europepmc   +1 more source

Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis. [PDF]

J Int Med Res
Yuan D, Cheng T, Cao Z, Wang F, Wang Y.
europepmc   +1 more source

Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial. [PDF]

J Am Heart Assoc
Knowlton KU, Navar AM, Anderson JL, Brown AS, Muhlestein JB, Kleeman K, Sarwat S, Abbas CA, Ramirez MA, Grines CL, Abo-Auda WS, Desai NR.   +11 more
europepmc   +1 more source

Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. [PDF]

Eur Heart J Qual Care Clin Outcomes
Engebretsen I, Ødegaard KM, Halvorsen S, Bugge C, Kristiansen IS, Støvring H, Munkhaugen J.   +6 more
europepmc   +1 more source

Correction: Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review. [PDF]

Cureus
Rabih AM, Niaj A, Raman A, Uprety M, Calero MJ, Villanueva MRB, Joshaghani N, Villa N, Badla O, Goit R, Saddik SE, Dawood SN, Mohammed L.   +12 more
europepmc   +1 more source